548. Respiratory Syncytial Virus Infection in Infants is Associated with Low Mortality in Rural Nepal
Session: Poster Abstract Session: Respiratory Viruses
Thursday, October 8, 2015
Room: Poster Hall
  • 20150928_IDSA_RSVInfantsFINAL.pdf (4.2 MB)
  • Background: Respiratory syncytial virus (RSV) is the most frequent cause of hospitalization in infants worldwide; the majority of disease burden is in resource-limited settings. The clinical presentation and illness characteristics of RSV infection in young infants are not well-described in populations where access to health care facilities are limited.

    Methods: As part of a randomized clinical trial of maternal influenza immunization in rural southern Nepal, infants were enrolled at birth and maternal and infant assessments were performed at a home visit shortly after birth. Infants were subsequently followed to six months of age with active weekly home-based surveillance for afebrile and febrile respiratory illness. A mid-nasal swab was taken and tested for RSV by RT-PCR for all illness episodes.

    Results: 327 (9%) of 3645 infants had a primary RSV illness episode, with 103 (32%) illnesses occurring at < 2 months of age. RSV was highly seasonal, with a peak between September and November over 3 seasons. Approximately half (n=184; 56%) of 327 infants with RSV were male. 76 (28%) of 274 were low birthweight, as compared to 505 (21%) of 2426 infants without RSV. No relationship was found between age at illness and birthweight (R2=0.0; P=0.32; Figure 1). As compared to older infants, infants with RSV at < 2 months of age had similar frequency of cough (88% vs. 86%; P=0.61), fever (63% vs. 56%; P=0.22), wheezing (61% vs. 65%; P=0.50) and total symptom duration (5.2 vs. 5.0 days; P=0.59). Two (0.01%) infants with RSV infection died.

    Conclusion: RSV caused a significant burden of respiratory illness in infants under age six months in rural Nepal, although mortality was low. Symptoms of RSV illness in younger and older infants were similar. In designing interventional trials in resource-limited settings, studies should consider clinical and virological endpoints other than hospitalization and mortality.

    Figure 1:

    Helen Chu, MD MPH, Medicine, University of Washington, Seattle, WA, Joanne Katz, ScD, Johns Hopkins University, Baltimore, MD, James Tielsch, PhD, Global Health, George Washington University, Washington, DC, Mark C. Steinhoff, MD, FIDSA, Division of Infectious Diseases, Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, Janet Englund, MD, FIDSA, Seattle Children's Hospital, Seattle, WA, Jane Kuypers, PhD, University of Washington, Seattle, WA, Steven C Leclerq, MPH, NNIPS, Baltimore, MD, Subarna Khatry, MBBS, DOMS, NNIPS, Kathmandu, Nepal and Amalia Magaret, PhD, Department of Laboratory Medicine, University of Washington, Seattle, WA


    H. Chu, Glaxo Smith Kline: Grant Investigator , Grant recipient

    J. Katz, None

    J. Tielsch, None

    M. C. Steinhoff, None

    J. Englund, None

    J. Kuypers, None

    S. C. Leclerq, None

    S. Khatry, None

    A. Magaret, None

    See more of: Respiratory Viruses
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.